Financials in USD. Standardized financial statements.
A compact view of how Pharmagreen Biotech Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3,410 | $2,998 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +13.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1,674 | $9,444 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $1,736 | -$6,446 | $0 | -$435,000 | -$435,000 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +50.9% | -215.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $249,918 | $467,563 | $1.07M | $752,729 | $485,748 | $652,105 | $669,797 | $18,986 | $69,682 | $1,669 |
| Operating Income? | -$248,000 | -$474,000 | -$1.07M | -$753,000 | -$677,000 | -$648,000 | -$670,000 | -$18,986 | -$69,682 | -$1,669 |
| EBITDA? | -$971,185 | $26,364 | $194,270 | -$3.76M | -$677,000 | $0 | -$72,310 | -$18,990 | -$69,682 | -$1,669 |
| Income Before Tax | -$1.00M | -$569,000 | -$876,000 | -$4.53M | -$2.48M | -$769,000 | -$1.07M | -$18,986 | -$69,682 | -$1,669 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $842,003 | $121,576 | $0 | $0 | $0 | $0 |
| Net Income? | -$1.00M | -$569,000 | -$875,000 | -$4.53M | -$2.44M | -$768,000 | -$1.07M | -$18,986 | -$69,682 | -$1,669 |
| EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.02 | $-0.03 | $-0.01 | $-0.04 | $-0.07 | $-0.26 | $-0.00 |
| Diluted EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.02 | $-0.03 | $-0.01 | $-0.04 | $-0.07 | $-0.26 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality